EIP
MRNA icon

Ellis Investment Partners’s Moderna MRNA Stock Holding History

Ellis Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-425
Closed -$50K – 530
2022
Q3 		$50K Hold
425
– – 0.01% 389
2022
Q2 		$60K Hold
425
– – 0.02% 380
2022
Q1 		$73K Buy
425
+225
+113% +$37.9K 0.02% 366
2021
Q4 		$50K Buy
+200
New +$58.5K 0.01% 423
2021
Q3 		– Sell
-10
Closed -$2K – 792
2021
Q2 		$2K Sell
10
-40
-80% -$7.15K ﹤0.01% 740
2021
Q1 		$7K Hold
50
– – ﹤0.01% 624
2020
Q4 		$5K Sell
50
-100
-67% -$10.1K ﹤0.01% 636
2020
Q3 		$10K Sell
150
-5
-3% -$349 ﹤0.01% 561
2020
Q2 		$9K Buy
155
+105
+210% +$5.75K ﹤0.01% 558
2020
Q1 		$1K Buy
+50
New +$1.15K ﹤0.01% 684

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ellis Investment Partners's MRNA Position: Q4 2022 in Review

Ellis Investment Partners sold out of Moderna (MRNA) in Q4 2022, closing a stake of 425 shares — an estimated $50K sold.

Ellis Investment Partners first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $73K in Q1 2022. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Ellis Investment Partners reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 425 Moderna shares in Q4 2022, an estimated $50K.
  • Ellis Investment Partners first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
  • Ellis Investment Partners's Moderna position peaked at $73K in Q1 2022.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.